Cargando…
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
Successful management of breast cancer in the metastatic setting is often confounded by resistance to chemotherapeutics, in particular anthracyclines and taxanes. The limited number of effective treatment options for patients with more aggressive biological subtypes, such as triple-negative metastat...
Autor principal: | Cristofanilli, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356906/ https://www.ncbi.nlm.nih.gov/pubmed/22645612 http://dx.doi.org/10.1155/2012/703858 |
Ejemplares similares
-
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer
por: Egerton, Nancy
Publicado: (2010) -
Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
por: Rak Tkaczuk, Katherine H.
Publicado: (2011) -
Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone
por: Rivera, Edgardo, et al.
Publicado: (2010) -
Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
por: Puhalla, Shannon, et al.
Publicado: (2008) -
Management of advanced breast cancer with the epothilone B analog, ixabepilone
por: Gradishar, William
Publicado: (2009)